Jerome A. Barakos

Neuroradiology

1101 Van Ness Ave
San Francisco, CA 94109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials.

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials.

Journal: CNS drugs

Published: November 10, 2025

Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities.

Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities.

Journal: AJNR. American journal of neuroradiology

Published: April 17, 2024

Validation of 3- and 5-point severity scales to assess ARIA-E.

Validation of 3- and 5-point severity scales to assess ARIA-E.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: July 19, 2023

Reply.

Reply.

Journal: AJNR. American journal of neuroradiology

Published: December 27, 2022

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: October 04, 2022

Comparing ARIA-E severity scales and effects of treatment management thresholds.

Comparing ARIA-E severity scales and effects of treatment management thresholds.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: August 15, 2022

Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice.

Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice.

Journal: AJNR. American journal of neuroradiology

Published: August 11, 2022

Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET.

Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: July 07, 2022

Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.

Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.

Journal: The journal of prevention of Alzheimer's disease

Published: May 11, 2022

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.

Journal: JAMA neurology

Published: November 22, 2021

Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.

Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.

Journal: BMC neurology

Published: March 26, 2021

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: May 31, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026